C5 and hemolytic-uremic syndrome: The patient was given C5 complement blocker Ravulizumab and started to display rapid improvement.<h4>Conclusion</h4>Although reports of HUS in the setting of COVID-19 continue to pour in, the questions of exact mechanism and similarities to MIS-C remain.